UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation | (Exact name of registrant as specified in its charter) | | | --- | --- | | Nevada | 26-1265381 | | (State or ...

Financial Data and Key Metrics Changes - The reported revenue for Q4 2022 was $19.7 million, a decrease of 3% from $20.3 million in the same period in 2021 [33] - The company expects a revenue increase of at least 10% year-over-year for the full year of 2023, with Q1 revenue guidance between $11.5 million and $13 million [13][49] - Gross margin for Q4 increased from 61% to 63%, with full-year 2023 gross margin guidance between 58% and 62% [8][33] Business Line Data and Key Metrics Changes - The average revenue for the top 20 pharmaceutical manufacturers declined nearly 14% year-over-year to $2.1 million due to extended deal closing timelines and higher turnover rates [13] - The net revenue retention rate declined to 90% due to macroeconomic factors impacting client programs [14] Market Data and Key Metrics Changes - The company reported a net loss of $325,000 in Q4 2022 compared to a net income of approximately $623,000 in Q4 2021 [10] - Cash flow from operations was $10.7 million for 2022, with $2.8 million generated in Q4 [11] Company Strategy and Development Direction - The company is following a land-and-expand strategy, focusing on delivering superior ROI, which remains above a 10:1 ratio [7] - The company aims to capture a greater portion of the available industry white space over the next three to five years, with total industry digital spend exceeding $10 billion [24][25] - The strategic positioning is expected to yield significant dividends over the next three to five years, with revenue projected to increase to multiples of current levels [31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the backlog being stronger than in previous years, indicating a potential for at least 10% growth [19][20] - The competitive landscape is crowded, but the company believes it has a unique data set and strong client response due to its integrated solutions [22][26] - Management acknowledged macroeconomic headwinds but noted positive trends since mid-2022, taking a conservative approach to guidance [49][52] Other Important Information - The company repurchased 1.2 million shares at an average price of $16.49, reducing total outstanding shares by nearly 7% [12] - Operating expenses increased to approximately $13.3 million in Q4 2022, primarily due to stock-based compensation and the EvinceMed acquisition [9][34] Q&A Session Summary Question: What is the revenue outlook for the year? - Management expects a drop in revenue of about 11% year-over-year in Q1 but anticipates 10% growth for the full year, with a stronger backlog [1][19] Question: How much of the growth is contracted versus needing to be won? - Typically, the company has 40% to 60% visibility for the rest of the year, which supports the 10% growth target [3] Question: What are the impacts of competition on specific products? - The competitive environment has increased, elongating the sales cycle, but the company believes its unique offerings will prevail [5][21] Question: What is the management's view on pharma's engagement with digital solutions? - There is a positive trend in pharma's engagement with digital solutions, with a focus on ROI and the need for effective communication with healthcare providers [39][42] Question: What are the expectations for the RWE pipeline? - The RWE pipeline contains several dozen deals, primarily from existing clients looking to upgrade, indicating a robust growth opportunity [69][70]

Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Chief Financi ...

Financial Data and Key Metrics Changes - Reported revenue for Q3 2022 was $15.1 million, a decrease of 6% from $16.1 million in Q3 2021, attributed to macro factors [17] - Gross margin increased from 56.3% in the previous year to 62.4% in Q3 2022 due to a favorable solution and network partner mix [17] - Operating expenses rose to approximately $13.2 million in Q3 2022 from about $9 million in the same period last year, primarily due to team expansion and the acquisition of EvinceMed [19] - GAAP net loss was $3.5 million in Q3 2022 compared to a net income of $0.04 million in Q3 2021; non-GAAP net income was approximately $1.3 million or $0.07 per share [20] - Cash, cash equivalents, and short-term investments totaled $78.8 million as of September 30, 2022, down from $87.4 million as of June 30, 2022, due to share buybacks [21] Business Line Data and Key Metrics Changes - The average revenue for top 20 pharmaceutical manufacturers decreased to $2.2 million at the end of Q3 2022 from $2.5 million in the previous year, influenced by delays in contract renewals [23] - Net revenue retention for Q3 2022 was 96%, a reduction compared to Q2 2022, driven by lower revenue growth [24] Market Data and Key Metrics Changes - The company is experiencing a shift in pharma manufacturers reallocating commercial spend towards omnichannel digital solutions, which is expected to capture a significant share of the market [10][15] - The company anticipates having at least six real-world evidence (RWE) deals running in the first half of 2023, which could contribute to over 20% top-line growth [11] Company Strategy and Development Direction - The company is focused on expanding its RWE solutions, which are seen as a significant growth driver aligned with digital trends in the life sciences industry [10][15] - The management emphasizes the importance of innovative partnerships and omni-channel strategies to enhance client relationships and improve gross margins [31] - The company aims to capture a larger market share as pharma spends shift from traditional methods to digital solutions, positioning itself for strong profitable growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism that macro headwinds will subside in 2023, with improvements in FDA drug approvals and employee turnover rates in the life sciences industry [6] - The company is confident in its ability to grow revenue and expand its partner network without needing additional capital for operating purposes [22] - Management highlighted the importance of maintaining a strong balance sheet and cash flow to support future growth opportunities [22] Other Important Information - The company has initiated a $20 million share repurchase program, having bought back 693,000 shares for $12.2 million at an average price of $17.66 [21] - The company continues to strengthen its channel network, recently renewing its exclusive partnership with NewCrop, enhancing its e-prescribing capabilities [14] Q&A Session Summary Question: Update on channel partners and gross margin - Management noted that channel partnerships are crucial, with a focus on innovative solutions that enhance client relationships and improve gross margins [31] Question: Confidence in Q4 guidance and seasonality - Management expressed a 95% confidence level in achieving the midpoint of the guidance, noting typical seasonal ramp-up in Q4 [33] Question: Details on RWE contracts and contributions to 2023 - Management confirmed that the new RWE contracts are multimillion-dollar deals, contributing positively to gross margins and revenue predictability [40] Question: Competitive landscape and market dynamics - Management indicated that smaller competitors are struggling to deliver on promises, leading to increased client interest in their solutions [42] Question: Retention rates and future expectations - Management believes retention rates are nearing the bottom and expects recovery as new contracts come online [53] Question: Revenue contribution from RWE and contract economics - Management clarified that RWE contracts can range from $0.5 million to $1.5 million in setup fees, transitioning to higher CPM distributions [60] Question: Guidance for Q4 and factors affecting it - Management attributed the wide guidance range to ongoing headwinds and the potential for client buy-ups [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdi ...

Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------|-------|-------|----------------- ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Joy Zhang - SVB Securities Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Marc Wiesenberger - B. Riley Securities Jeff Garro - Piper Sandler Operator Good afternoon, everyone. Thank you for joining OptimizeRx's Second ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction ...

OptimizeRx Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Ch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdictio ...